Am­gen catch­es a break as FDA re­jects Neu­las­ta knock­off; Zaf­gen gets a new CEO as Hugh­es moves to top sci­ence job

→ Am­gen caught a break to­day on its block­buster fran­chise drug Neu­las­ta. The FDA has re­ject­ed an ap­pli­ca­tion from Bio­con and My­lan for a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.